Related to ImmunoVaccine Technologies Collaborates with Scancell to Advance DNA Vaccine Delivery

• Crucell Receives $110M UNICEF Contract for Quinvaxem Pediatric Vaccine
  
• Advaxis Pads Listeria Vaccine IP through New Agreement with UPenn
  
• Virginia Commonwealth Uni to Evaluate Prophylactic CMV Vaccination Strategies with Vical
  
• Pevion to Use Cevec’s Protein-Expression Technology for Infectious Disease Vaccine
  
• Cytheris Scores €12M Financing to Progress IL-7 Pipeline
  
• Crucell and J&J to Develop RSV Vaccine
  
• Scancell and Immatics to Explore Combination of Vaccine Technologies for Colorectal Cancer
  
• Scancell Gains Rights to mAb from CRT for Immunotherapy Development
  
• NIH Bankrolls Six Centers with $100M to Characterize Human Immune Responses
  
• Okairos Obtains €16M to Advance T-Cell Vaccines for Infectious Diseases
  
• J&J and Crucell in Advanced Negotiations for €1.75B Acquisition Deal
  
• Immatics Raises Nearly €54M to Take Lead Therapeutic Cancer Vaccine into Phase III
  
• MedImmune Nabs Rights to IDC’s GLA Adjuvant for Infectious Disease Vaccines
  
• Cold Genesys Buys BioSante’s Oncolytic Virus Technology
  
• Theraclone Inks mAb Discovery Deal with Pfizer
  
• Amgen to Buy BioVex for $425M in Cash for Phase III-Stage Oncolytic Vaccine
  
• Inviragen and Duke-NUS Form Vaccine Partnership to Tackle Emerging Infectious Diseases
  
• Kite Pharma Raises $15M in Initial Private Placement to Progress Anticancer Pipeline
  
• Crucell to Use Pepscan’s CLIPS Technology for Development of Infectious Disease Vaccines
  
• MediGene Partners with Johns Hopkins to Progress AAVLP Vaccine Platform